Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine-Reference-Cited by-同舟云学术

Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine

Published:2023-06-18 Issue:8 Volume:40 Page:3559-3573
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Tanihara Hidenobu^ORCID,Yamamoto Tetsuya^ORCID,Aihara Makoto^ORCID,Koizumi Noriko^ORCID,Minami Hiroomi^ORCID,Kojima Satoshi,Isobe Tomoyuki,Kanazawa Mizuho,Suganami Hideki^ORCID,Owada Yasuko,Mikami Hiroshi,Yagi Michio,Furuie Hidetoshi,Hayashibara Tomoko,Kawai Eriko,Kano Kiyoshi,Mashimo Hisashi,Ando Makoto,Takat Masashi,

Funder

Kowa Company, Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02534-w.pdf

Reference42 articles.

1. Allison K, Patel D, Alabi O. Epidemiology of glaucoma: the past, present, and predictions for the future. Cureus. 2020;12:e11686.

2. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–34.

3. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–97.